Survival in HIV-1 patients receiving antiretroviral therapy in Morocco

被引:1
|
作者
Titou, H. [1 ]
Baba, N. [1 ]
Kasouati, J. [2 ]
Oumakir, S. [1 ]
Frikh, R. [1 ]
Boui, M. [1 ]
Hjira, N. [1 ]
机构
[1] Univ Mohammed V Rabat, Serv Dermatol Venerol, Hop Mil Instruct Mohamed V, Hay Ryad 10100, Morocco
[2] Univ Mohammed V Rabat, Lab Biostat & Rech Clin & Epidemiol, FMPR, Rabat, Morocco
来源
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE | 2018年 / 66卷 / 05期
关键词
Survival analysis; HIV infection; Antiretroviral therapy; PROTEASE INHIBITORS; HIV-1-INFECTED PATIENTS; INFECTED INDIVIDUALS; COHORT; MORTALITY; EFAVIRENZ; AIDS; DETERMINANTS; IMPACT; HETEROGENEITY;
D O I
10.1016/j.respe.2018.07.001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. - The purpose was to study factors associated with the survival of HIV-1 patients receiving antiretroviral therapy in Morocco. Material and method. - This was a retrospective study of a cohort of 182 HIV-1 patients receiving antiretroviral therapy in the department of dermatology venereology at the Military Instruction Hospital Mohamed V in Rabat during the period from 1 January 2006 to 1 January 2017. Death of any cause during the study period was considered to be the result of HIV infection. The log-rank test was used to compare the survival curves based on determinants. The Cox regression model analyzed the determinants of survival since induction of antiretroviral therapy. Results. - The median follow-up time was 4.7 years (IQR: 1.97-8.18). The mortality rate was 75 deaths per 1000 person-years. Advanced clinical stage CDC C (RR: 2.72; CI 95%: 1.33-5.56) and treatment with indinavir (RR: 1.41; CI 95%: 0.77-2.59) were significantly associated with death. Conclusion. - Initiation of antiretroviral therapy in the early stage of the disease and use of less toxic molecules are recommended to reduce mortality. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [1] Determinants of survival in HIV patients receiving antiretroviral therapy in Goma, Democratic Republic of Congo
    Akilimali, P. Z.
    Mutombo, P. B.
    Kayembe, P. K.
    Kaba, D. K.
    Mapatano, M. A.
    REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2014, 62 (03): : 201 - 206
  • [2] Risk Factors Associated with Unsuppressed Viral Load in HIV-1 Infected Patients at the First Antiretroviral Therapy in Morocco
    Hicham, Titou
    Ilyas, Elkassimi
    Tarik, Hanafi
    Noureddine, Baba
    Omar, Boudi
    Rachid, Frikh
    Naoufal, Hjira
    Mohammed, Boui
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2019, 8 (02) : 113 - 117
  • [3] Study of HIV-1 Drug Resistance in Patients Receiving Free Antiretroviral Therapy in China
    Xin-ping LI1
    2.State key laboratory for Infectious disease prevention and control
    3.Henan Center for Disease Control and Prevention
    4.Queshan Center for Disease Control and Prevention
    5.Graduate University of Chinese Academy of Sciences
    Virologica Sinica, 2007, (03) : 233 - 240
  • [4] Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients
    Weichseldorfer, Matthew
    Reitz, Marvin
    Latinovic, Olga S.
    PHARMACEUTICS, 2021, 13 (11)
  • [5] Survival Trend of HIV/AIDS Patients Starting Antiretroviral Therapy in South Korea between 2001 and 2015
    Kim, Yong Chan
    Ahn, Jin Young
    Kim, Hyo Youl
    Song, Joon Young
    Park, Dae Won
    Kim, Min Ja
    Choi, Hee-Jung
    Kim, Shin Woo
    Kee, Mee-Kyung
    Han, Myung Guk
    Yoo, Myeongsu
    Kim, Soo Min
    Choi, Yunsu
    Choi, Bo Youl
    Kim, Sang Il
    Choi, Jun Yong
    YONSEI MEDICAL JOURNAL, 2020, 61 (08) : 705 - 711
  • [6] HIV-1 Antiretroviral Drug Therapy
    Arts, Eric J.
    Hazuda, Daria J.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (04):
  • [7] Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia
    Alemu, Andinet Worku
    Sebastian, Miguel San
    GLOBAL HEALTH ACTION, 2010, 3
  • [8] Antiretroviral therapy of HIV-infected patients
    Gölz, J
    MEDIZINISCHE WELT, 1999, 50 (06): : 223 - 229
  • [9] Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy
    Chen, YMA
    Rey, WY
    Can, YC
    Lai, SF
    Huang, YC
    Wu, SI
    Liu, TT
    Hsiao, KJ
    JOURNAL OF BIOMEDICAL SCIENCE, 2003, 10 (02) : 266 - 275
  • [10] Incidence of and risk factors for liver damage in patients with HIV-1 mono-infection receiving antiretroviral therapy
    Huang, Huihuang
    Song, Bing
    Gao, Lin
    Cheng, Juan
    Mao, Yufeng
    Zhao, Hua
    Tu, Bo
    Huang, Shun
    Zhang, Jieli
    Chen, Dianjie
    Zhao, Peng
    Jiao, Yan-Mei
    Jiang, Tianjun
    HIV MEDICINE, 2022, 23 : 14 - 22